Non Small Cell Lung Cancer Clinical Trials in Minneapolis, Minnesota

9 studies are recruiting for non small cell lung cancer in Minneapolis, Minnesota right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

   This is a first in human, open-label, multi-center Phase 1 / 2 study to evaluate the safety, tolerability, and initial efficacy of AU-007, also known as imneskibart, in patients with advanced solid tumors. AU-007 will be administered either as a monotherapy, or in combination with a single loading …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Minnesota Oncology and Hematology PA, Minneapolis, Minnesota

   Locations

   17 in total

   Run by

   Aulos Bioscience, Inc.

   See if you can join NCT05267626 on ClinicalTrials.gov

2. Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

   Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Clinical Study Site, Minneapolis, Minnesota

   Locations

   285 in total

   Run by

   Summit Therapeutics

   See if you can join NCT06767514 on ClinicalTrials.gov

3. A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

   This study will assess if adding sacituzumab tirumotecan with pembrolizumab after surgery is effective in treating NSCLC for participants not achieving pathological complete response. The primary hypothesis of this study is sacituzumab tirumotecan plus pembrolizumab is superior to pembrolizumab mon…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Allina Health Cancer Institute - Abbott Northwestern Hospital ( Site 0027), Minneapolis, Minnesota

   Locations

   269 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06312137 on ClinicalTrials.gov

4. Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

   BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies in participants with selected advanced malignancies. The stu…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Masonic Cancer Center University of Minnesota, Minneapolis, Minnesota

   Locations

   49 in total

   Run by

   Institut de Recherches Internationales Servier

   See if you can join NCT05786924 on ClinicalTrials.gov

5. Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

   This is a phase 3 study of pembrolizumab in combination with carboplatin/taxane (paclitaxel or nab-paclitaxel) followed by pembrolizumab with or without maintenance sacituzumab tirumotecan (sac-TMT; MK-2870) in first-line treatment of metastatic squamous non-small cell lung cancer. It is hypothesiz…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Allina Health Cancer Institute - Abbott Northwestern Hospital ( Site 0146), Minneapolis, Minnesota

   Locations

   216 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06422143 on ClinicalTrials.gov

6. FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

   This is a Phase 1 study of FT836 administered in participants with advanced solid tumors. The primary objectives of the study are to evaluate the safety and tolerability of FT836 with or without chemotherapy and/or trastuzumab or cetuximab, and to determine the recommended phase 2 dose (RP2D) of FT…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota

   Locations

   5 in total

   Run by

   Fate Therapeutics

   See if you can join NCT07216105 on ClinicalTrials.gov

7. Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

   This study is being done to find out if a new medicine called PF-08634404, when given with chemotherapy, works better than the present standard treatment (pembrolizumab with chemotherapy) for adults with a type of lung cancer called non-small cell lung cancer (NSCLC) that is either locally advanced…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Allina Health Cancer Institute - Abbott Northwestern Hospital, Minneapolis, Minnesota

   Locations

   440 in total

   Run by

   Pfizer

   See if you can join NCT07222566 on ClinicalTrials.gov

8. This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

   The purpose of the study is to compare how the new combination treatment (Sigvotatug Vedotin plus pembrolizumab) works compared to pembrolizumab alone in patients with non-small cell lung cancer (NSCLC) with high levels of PD-L1. This is a protein that acts as a kind of "brake" to keep the body's i…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Hennepin County Medical Center, Minneapolis, Minnesota

   Locations

   372 in total

   Run by

   Pfizer

   See if you can join NCT06758401 on ClinicalTrials.gov

9. Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

   Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. Head and Neck Squamous Cell Carcinoma (HNSCC) is a solid tumor, a disease in which ca…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   M Health Fairview University of Minnesota Medical Center - East Bank /ID# 276200, Minneapolis, Minnesota

   Locations

   48 in total

   Run by

   AbbVie

   See if you can join NCT05005403 on ClinicalTrials.gov